AI assistant
Vanda Pharmaceuticals Inc. — Director's Dealing 2024
Mar 6, 2024
33390_dirs_2024-03-06_54a19182-ceab-4ce4-84f1-d259e35f8350.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2024-03-04
Reporting Person: Wijkstrom Joakim (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-04 | Common Stock | S | 7498 | $4.4133 | Disposed | 139018 | Direct |
| 2024-03-05 | Common Stock | S | 9229 | $4.2074 | Disposed | 129789 | Direct |
Footnotes
F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.38 to $4.4402, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.2027 to $4.225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.